Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504057 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL3899055 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL3158180 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL9504052 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL29425221 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL476387 | 1.00 | PAX8 (0.44) | PAX8 | |
| SCHEMBL4459290 | 1.00 | PAX8 (0.44) | PAX8 | |
| Hydrochloric Acid SCHEMBL1722152 | 0.97 | PAX8 (0.43) | PAX8 | |
| SCHEMBL14151119 | 0.97 | PAX8 (0.43) | PAX8 | |
| SCHEMBL11403360 | 0.97 | PAX8 (0.43) | PAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 452 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107335-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATIC DISEASES BY INHIBITING EFHD1 | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | OCTARINE BIO APS (DK) | 2026-04-02 | — | — | US | claimed |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | SHANGHAI JUNSHI BIOSCIENCES CO LTD (CN) | 2025-10-30 | — | — | US | claimed |
| US-20250213698-A1 | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2025-07-03 | — | — | US | claimed |
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ARCTURUS THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | claimed |
| WO-2025083657-A1 | LIPID COMPOUND AND COMPOSITION FOR TISSUE-SPECIFIC DELIVERY OF ACTIVE SUBSTANCE | 한국생명공학연구원 | 2025-04-24 | — | — | WO | claimed |
| EP-4499830-A1 | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | Hansoh Bio LLC (US) | 2025-02-05 | — | — | EP | claimed |
| US-20250034080-A1 | CATIONIC LIPID CONTAINING SIDE-CHAIN FUNCTIONAL GROUPS AND APPLICATION THEREOF | XIAMEN SINOPEG BIOTECH CO., LTD. (CN) | 2025-01-30 | — | — | US | claimed |
| US-20240392289-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | Hepagene Therapeutics (HK) Limited (CN) | 2024-11-28 | — | — | US | claimed |
| EP-4458805-A1 | CATIONIC LIPID CONTAINING FUNCTIONAL GROUP ON SIDE CHAIN, AND USE THEREOF | Xiamen Sinopeg Biotech Co., Ltd. (CN) | 2024-11-06 | — | — | EP | claimed |
| US-20170028074-A1 | MultiLigand Agent for Drug Delivery | ARCTURUS THERAPEUTICS, INC. | 2017-02-02 | — | — | US | claimed |
| EP-2456772-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PROTECTING BRAIN HEALTH IN NEURODEGENERATIVE DISORDERS | Amazentis SA (CH) | 2012-05-30 | — | — | EP | claimed |
| WO-2011011721-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR PROTECTING BRAIN HEALTH IN NEURODEGENERATIVE DISORDERS | AMAZENTIS SA (CH) | 2011-01-27 | — | — | WO | claimed |
| US-20090325891-A1 | Cartilage regeneration-promoting agent | EISAI FOOD & CHEMICAL CO., LTD. | 2009-12-31 | — | — | US | claimed |
| WO-2007099392-A2 | CONVERGENT SYNTHESIS OF CARBOHYDRATE BUILDING BLOCKS | SWISS FEDERAL INSTITUTE OF TECHNOLOGY (US) | 2007-09-07 | — | — | WO | claimed |
| EP-0320960-B1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1993-05-12 | — | — | EP | claimed |
| US-5145848-A | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1992-09-08 | — | — | US | claimed |
| EP-0396588-A1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1990-11-14 | — | — | EP | claimed |
| WO-1989005815-A1 | AMINO ANTHRACENEDIONES-BIS PLATINUM COMPLEXES, USEFUL AS ANTITUMORAL AGENTS | BOEHRINGER BIOCHEMIA ROBIN S.P.A. (IT) | 1989-06-29 | — | — | WO | claimed |
| EP-0320960-A1 | Amino anthracenediones-bis platinum complexes, useful as antitumoral agents | BOEHRINGER MANNHEIM ITALIA S.P.A. (IT) | 1989-06-21 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092179-A1 | GENETICALLY MODIFIED HOST CELLS PRODUCING VIOLACEIN, ANALOGUES, AND DERIVATIVES THEREOF | TDO2, BLVRB, INMT | PAX8 4054/4885 |
| US-12290567-B2 | Asialoglycoprotein Receptor mediated delivery of therapeutically active conjugates | ASGR1, FCGR2A, FCGR3B | PAX8 4083/4885 |
| US-20240392289-A1 | LIGAND CONJUGATES FOR DELIVERY OF THERAPEUTICALLY ACTIVE AGENTS | FCGR2A, ASGR1, APLNR | PAX8 3532/4885 |
| US-20250333730-A1 | SIRNA FOR INHIBITING ANGPTL3 GENE EXPRESSION AND USE THEREOF | TEK, TIE1, PCSK9 | PAX8 3007/4885 |
| US-20170028074-A1 | MultiLigand Agent for Drug Delivery | NPC1L1, LDLR, CETP | PAX8 4133/4885 |
| US-20250213698-A1 | BICYCLIC HETEROCYCLES AND THEIR LIGANDS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS | PAICS, ABCG2, FOLR1 | PAX8 4511/4885 |
| US-20090325891-A1 | Cartilage regeneration-promoting agent | HGF, COL2A1, HDGF | PAX8 163/4885 |
| US-20250034080-A1 | CATIONIC LIPID CONTAINING SIDE-CHAIN FUNCTIONAL GROUPS AND APPLICATION THEREOF | PHOSPHO1, LIPA, SLC7A1 | PAX8 4861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.